Multiple myeloma screening: Difference between revisions
Shyam Patel (talk | contribs) |
m (Bot: Removing from Primary care) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Multiple myeloma}} | {{Multiple myeloma}} | ||
{{CMG}} {{AE}}{{HL}} {{shyam}} | {{CMG}} {{AE}}{{HL}}; {{shyam}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for multiple myeloma in the general population. | There is insufficient evidence to recommend routine screening for multiple myeloma in the general population. However, laboratory assessment should be done often (typically once per year or more frequently) for patients who have monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. | ||
==Screening== | ==Screening== | ||
=== | ===Monoclonal gammopathy of undetermined significance=== | ||
[[Monoclonal gammopathy of undetermined significance]] (MGUS) carries a 1% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of [[complete blood count]] (CBC), [[serum protein electrophoresis]] (SPEP), and [[free light chain]] ratio typically once yearly. The frequency of screening may vary depending on the MGUS risk group. High-risk patients may need more frequent monitoring because high-risk MGUS carries a higher risk for progression to multiple myeloma. High-risk MGUS is defined by the presence of M-spike > 1.5g/dl, non-IgG subtype of the [[paraprotein]], and abnormal free light chain ratio.<ref name="pmid21888255">{{cite journal| author=Kyle RA, Rajkumar SV| title=Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). | journal=Oncology (Williston Park) | year= 2011 | volume= 25 | issue= 7 | pages= 578-86 | pmid=21888255 | doi= | pmc=3923465 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21888255 }} </ref> | [[Monoclonal gammopathy of undetermined significance]] (MGUS) carries a 1% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of [[complete blood count]] (CBC), [[serum protein electrophoresis]] (SPEP), and [[free light chain]] ratio typically once yearly. The frequency of screening may vary depending on the MGUS risk group. High-risk patients may need more frequent monitoring because high-risk MGUS carries a higher risk for progression to multiple myeloma. High-risk MGUS is defined by the presence of M-spike > 1.5g/dl, non-IgG subtype of the [[paraprotein]], and abnormal free light chain ratio.<ref name="pmid21888255">{{cite journal| author=Kyle RA, Rajkumar SV| title=Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). | journal=Oncology (Williston Park) | year= 2011 | volume= 25 | issue= 7 | pages= 578-86 | pmid=21888255 | doi= | pmc=3923465 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21888255 }} </ref> | ||
===[[Smoldering multiple myeloma]]=== | ===[[Smoldering multiple myeloma]]=== | ||
[[Smoldering multiple myeloma]] carries a 10% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of [[complete blood count]] (CBC), [[serum protein electrophoresis]] (SPEP), and [[free light chain]] ratio typically once yearly or more frequently. The frequency of screening may vary depending on the smoldering multiple myeloma risk group. High-risk smoldering multiple myeloma patients may need more frequent monitoring | [[Smoldering multiple myeloma]] carries a 10% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of [[complete blood count]] (CBC), [[serum protein electrophoresis]] (SPEP), and [[free light chain]] ratio typically once yearly or more frequently. The frequency of screening may vary depending on the smoldering multiple myeloma risk group. High-risk smoldering multiple myeloma patients may need more frequent monitoring since this carries a higher risk for progression to active multiple myeloma. | ||
===Multiple myeloma=== | ===Multiple myeloma=== | ||
There is insufficient evidence to recommend routine screening for active multiple myeloma in the general population, but patients with MGUS or smoldering multiple myeloma should have routine laboratory checks to monitor for progression to active multiple myeloma.<ref name="n">Multiple Myeloma Prevention and Screening.(2015)http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/multiple-myeloma/prevention/index.html</ref><ref name="r">Can multiple myeloma be prevented?(2015)http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-prevention</ref> | There is insufficient evidence to recommend routine screening for active multiple myeloma in the general population, but patients with MGUS or smoldering multiple myeloma should have routine laboratory checks to monitor for progression to active multiple myeloma.<ref name="n">Multiple Myeloma Prevention and Screening.(2015)http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/multiple-myeloma/prevention/index.html</ref><ref name="r">Can multiple myeloma be prevented?(2015)http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-prevention</ref> | ||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Surgery]] | |||
Latest revision as of 22:47, 29 July 2020
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma screening On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma screening |
|
Risk calculators and risk factors for Multiple myeloma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]; Shyam Patel [3]
Overview
There is insufficient evidence to recommend routine screening for multiple myeloma in the general population. However, laboratory assessment should be done often (typically once per year or more frequently) for patients who have monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Screening
Monoclonal gammopathy of undetermined significance
Monoclonal gammopathy of undetermined significance (MGUS) carries a 1% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of complete blood count (CBC), serum protein electrophoresis (SPEP), and free light chain ratio typically once yearly. The frequency of screening may vary depending on the MGUS risk group. High-risk patients may need more frequent monitoring because high-risk MGUS carries a higher risk for progression to multiple myeloma. High-risk MGUS is defined by the presence of M-spike > 1.5g/dl, non-IgG subtype of the paraprotein, and abnormal free light chain ratio.[1]
Smoldering multiple myeloma
Smoldering multiple myeloma carries a 10% annual risk (on average) for progression to active multiple myeloma and therefore requires monitoring. Given the risk of progression, patients should be screened via monitoring of complete blood count (CBC), serum protein electrophoresis (SPEP), and free light chain ratio typically once yearly or more frequently. The frequency of screening may vary depending on the smoldering multiple myeloma risk group. High-risk smoldering multiple myeloma patients may need more frequent monitoring since this carries a higher risk for progression to active multiple myeloma.
Multiple myeloma
There is insufficient evidence to recommend routine screening for active multiple myeloma in the general population, but patients with MGUS or smoldering multiple myeloma should have routine laboratory checks to monitor for progression to active multiple myeloma.[2][3]
References
- ↑ Kyle RA, Rajkumar SV (2011). "Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)". Oncology (Williston Park). 25 (7): 578–86. PMC 3923465. PMID 21888255.
- ↑ Multiple Myeloma Prevention and Screening.(2015)http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/multiple-myeloma/prevention/index.html
- ↑ Can multiple myeloma be prevented?(2015)http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-prevention